During the COVID-19 pandemic, SaNOtize developed its first product — a nitric oxide (NO)-based nasal spray — shown to be effective against intranasal viruses, including SARS-CoV-2. The nasal spray is now registered or approved in more than 20 countries worldwide. Its approval in India marked the first-ever regulatory authorization of a NO-releasing drug to treat an infection. 

 In some markets, the nasal spray is available as a wellness product without treatment or prevention claims. In others, it may be registered with antiviral prevention or treatment claims, depending on the country’s regulatory framework. 

 SaNOtize is also advancing a pipeline of topical products designed for skin and nail conditions—bringing nitric oxide to modern dermatology and podiatry. These include cleansers and gels for use by individuals with plantar warts, nail fungus (onychomycosis), athlete’s foot, and other infections. Depending on market regulations, these products may be offered as wellness products, over-the-counter cleansers, or therapeutic treatments. 

 The company is guided by a distinguished Board of Directors, comprising global leaders in science, medicine, and business. 

 Nitric oxide has the potential to save lives and improve the quality of life for hundreds of millions of people worldwide. 

Some of the products discussed on the pages of this website may not be approved in Canada or the United States, and certain claims may not have been reviewed by the regulatory authorities in each country.